Clinical Trial: Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07795268) titled 'Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)' on Aug. 26.

Brief Summary: The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Prostate Cancer

Intervention: DRUG: 177Lu-NYM032 injection

Administered intravenously once every...